Figure 3.

Ratio of subsets of NK cells. Graphs show the ratios of CD16^bright:CD16^dim NK cells in (A) patient A, (B) patient B and (C) patient C prior to, during and subsequent to therapy with the tyrosine kinase inhibitor sunitinib. Arrows indicate the time points when the treatment regimen was changed (from sunitinibto everolimus in patient B, and from sunitinibto sorafenib in patient C). (D) The mean + standard deviation of three measurements are shown for each of the healthy donor controls (nos. 1–4). NK cells, natural killer cells; CD16, cluster of differentiation 16.